With the evolution of biotechnology, addressing allergy treatments for children offers hope for a future where the young can lead lives unrestricted by common food allergens.
A pre-clinical stage Biotech Company aimed to develop its first product for novel food allergy treatment in children through clinical proof of concept before partnering with a global pharmaceutical firm and its currently raising capital to support pre-clinical development program.
With the collaborative assistance of Biointelect, the company’s venture to secure investors was strategically streamlined, ensuring their pioneering approach to children’s food allergy treatments was robustly supported, well-researched, and optimally positioned in the market.
With oncology treatments rapidly growing in interest, the quest to refine and perfect drug delivery mechanisms is paramount. Utilising nanoparticles, a biotech company stands on the verge of reformulating three approved oncology drugs, targeting the expansive US and EU markets.
Biointelect has played a critical role in sculpting the company’s strategy, from inception to investor readiness. It is with Biointelect’s assistance that the biotech company could pivot from concept to a formidable market contender, with a clear and strategic vision for investor engagement.
In the realm of drug and device regulations, having a partner to navigate the complexities can significantly alter a company’s trajectory.
Biointelect collaborated with an early-stage Australian manufacturing firm, crafting a preliminary regulatory strategy for their innovative drug device combination, ensuring they’re not just compliant but also competitive.
At the crossroads of innovation and regulation, the firm sought a strategic compass which they found in Biointelect. This partnership ensured the firm was not only set on a path of compliance but also primed for success in the competitive drug-device landscape.
In an era of rapid advancements in medical technology, the journey to propel RNA therapeutics to the forefront of healthcare solutions is a testament to collaborative innovation.
The NSW Government and the NSW RNA Bioscience Alliance have committed AU$ 96 million to build the RNA pilot facility and an additional AU$ 119 million for operating costs until 2035.
The new facility will conduct small-scale production of messenger RNA (mRNA), synthetic RNA (sRNA) and lipid nanoparticles (LNP) encapsulation at a scale which will enable clinical trials of new therapeutics.
Viruses, cancers, genetic diseases and many other health-related issues are potentially treatable with RNA technologies.